1. Home
  2. NOMD vs CAPR Comparison

NOMD vs CAPR Comparison

Compare NOMD & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nomad Foods Limited

NOMD

Nomad Foods Limited

HOLD

Current Price

$10.06

Market Cap

1.4B

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$28.05

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOMD
CAPR
Founded
2014
2005
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2015
2011

Fundamental Metrics

Financial Performance
Metric
NOMD
CAPR
Price
$10.06
$28.05
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
$12.50
$44.63
AVG Volume (30 Days)
1.1M
775.7K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
7.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.45
$3.31
P/E Ratio
$8.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.99
$4.30
52 Week High
$18.33
$40.37

Technical Indicators

Market Signals
Indicator
NOMD
CAPR
Relative Strength Index (RSI) 47.70 49.30
Support Level $9.52 $25.76
Resistance Level $10.49 $30.21
Average True Range (ATR) 0.24 1.28
MACD -0.00 0.13
Stochastic Oscillator 31.95 56.05

Price Performance

Historical Comparison
NOMD
CAPR

About NOMD Nomad Foods Limited

Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: